Allie R. Kehret

Allie R. Kehret

Auto-generated profile, based on publicly available information

Allie R. Kehret

Fred Hutchinson Cancer Center, Seattle, Washington, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
GLGeorge S. Laszlo
George S. Laszlo
JOJohnnie J. Orozco
Johnnie J. Orozco
AKAllie R. Kehret
Allie R. Kehret
MLMargaret C. Lunn
Margaret C. Lunn
JHJenny Huo
Jenny Huo
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter

21 March 2025 in Leukemia
Verified
Journal Article
Closed access
PDF file
FCFrances M. Cole
Frances M. Cole
GLGeorge S. Laszlo
George S. Laszlo
MLMargaret C. Lunn-Halbert
Margaret C. Lunn-Halbert
AKAllie R. Kehret
Allie R. Kehret
PZPatrick A. Zweidler-McKay
Patrick A. Zweidler-McKay
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter

1 June 2026 in Blood
Verified
Journal Article
Open access
SRStefan Radtke
Stefan Radtke
GLGeorge S. Laszlo
George S. Laszlo
KSKyle Swing
Kyle Swing
ARAndrea Repele
Andrea Repele
JBJacob W Barton
Jacob W Barton
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter
Successful transplantation of autologous gene-modified hematopoietic stem/progenitor cells (HSPCs) requires efficient ablation of resident hematopoietic stem cells. Since conventional myeloablative conditioning regimens are associated with non-hematologic toxicities, we evaluated CD45-directed radioimmunotherapy (RIT) using the a-emitter astatine-211 (211At) before transplantation of ex vivo gene-edited autologous HSPCs as an alternative in nonhuman primates. We humanized the CD45 antibody, BC8 (HuBC8), and labeled it with 211At. As a model, mobilized CD34+ HSPCs were multiplex gene-edited using an adenine base editor, modifying the HBG promoter to reactivate fetal hemoglobin (HbF) and deleting CD33. Two animals each received 300 or 400 µCi/kg of 211At. In contrast to historic controls conditioned with total body irradiation, CD45-RIT animals did not show any noticeable non-hematopoietic toxicities and were almost entirely transfusion independent with rapid recovery of neutrophils and platelets. 211At enabled dose-dependent engraftment of gene-edited cells. A new single cell sequencing assay revealed up to 70% combined mono- and bi-allelic gene-editing efficiency in the blood, consistent with complete replacement of the bone marrow stem cell compartment. Assessment by bulk analysis underestimated the frequency of gene-edited cells, highlighting the importance of a single cell readout. Single cell sequencing further confirmed stable and unbiased contribution of multiplex-edited HSPCs to all mature lineages in the blood, providing high-resolution data assuring successful replacement upon autologous HSPC gene therapy. Levels of edited cells remained stable for the entire follow-up of >18 months. Together, these studies identify 211At-CD45 RIT as a targeted alternative for myeloablative conditioning for autologous gene therapy.